Comparing two blood thinners for atrial fibrillation and heart disease
Part of Heart & circulation clinical trials.
This study compares two blood-thinning medicines, edoxaban and apixaban, to see which one is better at preventing strokes and bleeding in people who have both atrial fibrillation and coronary artery disease. If you're eligible, you may receive one of these standard treatments, and the trial could help find the safer option.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 19 years old.
- You have atrial fibrillation (irregular heartbeat) that requires a blood thinner, and you have a higher risk of stroke (score of 2 or more on the CHA2DS2-VASc scale).
- You also have coronary artery disease. This can be a history of a heart procedure like a stent (PCI) or bypass surgery, or a narrowing of at least 50% in a major heart artery.
- You must not have severe kidney problems (dialysisor very low kidney function) or active major bleeding.
- You are not pregnant or breastfeeding.
- You can give informed consent to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests the safety of a new blood thinner for people with atrial fibrillation (AFib) who need long-term stroke prevention. If you qualify, the study will compare this medication to standard anticoagulation therapy.
This study tests a new blood thinner to prevent strokes and blood clots in people with atrial fibrillation (a common heart rhythm problem). You may qualify if you have atrial fibrillation and at least one risk factor for stroke, or if you've never taken a blood thinner before.
This trial compares two types of blood thinners (DOACs like apixaban or rivaroxaban, and warfarin) to see which works better for people who have a stroke while taking a DOAC. The goal is to find the safest and most effective option to prevent another stroke.
This trial is testing two blood thinners (edoxaban and apixaban) to see how they compare in preventing new brain spots on MRI after a stroke in people with atrial fibrillation. It may help you and your doctor choose the safer option.
This study compares two commonly used blood thinners (apixaban and rivaroxaban) to see which works better for people with non-valvular atrial fibrillation, a type of irregular heartbeat. The goal is to find the safest and most effective option for preventing strokes.
This trial compares the bleeding risk of two commonly used blood thinners—rivaroxaban and apixaban—in people with atrial fibrillation (AF). If you’re starting an anticoagulant for a new AF diagnosis, this may help doctors choose the safer option for you and others.
Hear when a new Coronary Arterial Disease (CAD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.